Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2
|ClinicalTrials.gov Identifier: NCT00967239|
Recruitment Status : Unknown
Verified May 2015 by NSABP Foundation Inc.
Recruitment status was: Active, not recruiting
First Posted : August 27, 2009
Last Update Posted : May 8, 2015
RATIONALE: Studying the genes expressed in samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood samples from high-risk postmenopausal women who received treatment on breast cancer prevention clinical trials NSABP-P-1 or NSABP-P-2.
|Condition or disease||Intervention/treatment|
|Breast Cancer||Genetic: DNA analysis Genetic: polymorphism analysis Other: laboratory biomarker analysis Other: pharmacogenomic studies|
- To identify genes associated with breast events (i.e., the occurrence of invasive breast cancer or ductal carcinoma in situ), in terms of single-nucleotide polymorphisms (SNPs) in a genome-wide association study, in Caucasian women at high risk of developing breast cancer who have received a selective estrogen receptor modulator (SERM) (i.e., tamoxifen or raloxifene) on the NSABP-P-1 OR NSABP-P-2 breast cancer prevention clinical trials.
- To determine the impact of CYP2D6 metabolizer status, which includes genotype and status of concurrent use of CYP2D6 inhibitors, on breast cancer events in participants receiving either tamoxifen or raloxifene.
- To explore whether multiple SNPs within a region are independently associated with a breast event.
- To explore whether there are interactions among SNPs that increase the risk for a breast event.
- To explore whether there is interaction of any SNPs identified in the primary objective with randomized treatment, in terms of the risk for a breast event.
- To identify rare variants that might affect estrogen-dependent expression of chromosomes (CTSO) 4 and 16 (ZNF423) and/or the relationship to BRCA1 expression.
OUTLINE: Samples are stratified according to CYP2D6 genotype and CYP2D6 metabolizer status.
DNA extracted from previously collected blood samples is analyzed in a genome-wide association study and compared with 2 control samples from patients who did not experience a breast event. DNA samples are used to identify and analyze single nucleotide polymorphisms.
Also, exploratory analyses are conducted examining the impact of CYP2D6 metabolizer status on breast cancer events according to invasive vs non-invasive disease, ER status, PgR status, histologic type, and TMN stage.
|Study Type :||Observational|
|Estimated Enrollment :||1881 participants|
|Observational Model:||Case Control|
|Official Title:||The Pharmacogenomics of Breast Cancer Prevention: A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2|
|Study Start Date :||April 2009|
|Estimated Primary Completion Date :||December 2015|
- Identification of genes, as measured by single-nucleotide polymorphisms (SNPs), that are associated with breast events [ Time Frame: Approximately 6 years ]Retrospective study design: SNPs associated with available breast cancer events
- Impact of CYP2D6 metabolizer status on breast cancer events [ Time Frame: Approximately 6 years ]Retrospective study design: assay results associated with available breast cancer events
- Exploration of whether SNPs within a region are independently associated with a breast event [ Time Frame: Approximately 6 years ]Retrospective study design: assay results associated with available breast cancer events
- Exploration of whether interactions among SNPs increase the risk for a breast event [ Time Frame: Approximately 6 years ]Retrospective study design: results associated with available breast cancer events
- Exploration of whether SNPs have an effect on treatment [ Time Frame: Approximately 6 years ]Retrospective study design: SNPs associated with appropriate treatment information
Biospecimen Retention: None Retained
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00967239
|Study Chair:||James N. Ingle, MD||Mayo Clinic|